| 查看: 80 | 回复: 2 | |||
| 当前主题已经存档。 | |||
| 【有奖交流】积极回复本帖子，参与交流，就有机会分得作者 252314515 的 10 个金币 | |||
[交流]
紧急求助Drugs上的一篇文献
|
|||
|
各位虫友：我现在急需下面的文献，请大家帮一下忙。谢谢！！！ New approaches to influenza chemotherapy - Neuraminidase inhibitors Source: DRUGS Volume: 56 Issue: 4 Pages: 537-553 Published: OCT 1998 |
回复此楼» 猜你喜欢
一志愿0817化学工程与技术，求调剂
已经有8人回复
-
271分求调剂学校
已经有3人回复
-
285求调剂
已经有4人回复
-
生物学308分求调剂（一志愿华东师大）
已经有7人回复
-
296材料专硕求调剂
已经有18人回复
-
材料与化工306分找调剂
已经有18人回复
-
302求调剂
已经有9人回复
-
一志愿北京科技大学材料工程085601，求调剂
已经有11人回复
-
283分材料与化工求调剂
已经有19人回复
-
326求调剂
已经有8人回复
|
Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, USA. Epidemic influenza continues to be associated with significant morbidity in the general population, and mortality in the elderly and other high risk patients. Although the case fatality rate averages less than 0.01%, tens of thousands of deaths occur each year. Control through immunisation programmes has not been possible due to incomplete protective efficacy and antigenic variations that occur frequently. Currently available anti-influenza medications (amantadine and rimantadine) have had limited success due to underutilisation, lack of activity against influenza B, the rapid development of viral resistance to the drugs, and adverse effects. A new class of antiviral agents designed to inhibit influenza neuraminidase, an important surface glycoprotein, is currently under active development for use in the prophylaxis and treatment of influenza A and B infections. Two of these compounds, zanamivir (GG167) and GS4104 (the ethyl ester prodrug of GS4071) have reached clinical trials. Most studies of zanamivir have involved topical administration by inhalation of dry powder aerosols and/or intranasal doses of aqueous solutions. These routes rapidly provide high local concentrations at the sites of delivery. GS4104 is administered orally, which allows for greater ease of administration, and probably more uniform distribution of the parent compound GS4071 in the respiratory tract. Both have shown potent inhibitory activity against influenza in animal models and experimental human influenza with excellent tolerability profiles. Zanamivir treatment has been shown to reduce the severity and duration of naturally occurring, uncomplicated influenza illness in adults. Clinical resistance to these drugs has not been recognised as a significant problem to date, although strains resistant to each agent have been produced in the laboratory. This class of agents shows considerable promise as a novel approach to prophylaxis and treatment of influenza infections. Ongoing studies should provide the data needed to allow the addition of 1 or more of the neuraminidase inhibitors to the clinician's anti-influenza armamentarium. |
2楼2008-08-30 10:38:33
3楼2008-08-30 21:56:15
